Japan, Feb. 24 -- BIOSCEPTRE AUST PTY LTD has got intellectual property rights for 'CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF.' Other related details are as follows:
Application Number: JP,2023-047606
Category (FI): A61K35/12,A61K35/17,A61K35/76,A61K39/395@E,A61K39/395@T,A61K40/10,A61K40/11,A61K40/15,A61K40/31,A61K40/42,A61K47/68,A61K48/00,A61P35/00,A61P35/02,C07K14/705,C07K16/28,C07K19/00,C12N15/115@Z,C12N15/13,C12N15/62@Z,C12N15/86@Z,C12N5/0783,C12N5/10
Stage: PROBLEM TO BE SOLVED: To provide a chimeric antigen receptor (CAR) targeting a tumour-associated antigen which is selectively expressed by cancerous cells but not endogenously expressed on non-cancerous cells.SOLUTION: A chimeric antigen receptor includes domains including an antigen-recognition domain which recognises an epitope, wherein the epitope binds to the dysfunctional P2X7 receptor, a transmembrane domain, and a signalling domain including an intracellular signalling site of an activation receptor and/or an intracellular signalling site of a costimulatory receptor.SELECTED DRAWING: Figure 1 (Grant)
Filing Date: March 24, 2023
Publication Date: June 13, 2023
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
